ARWR

SEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 8

O'Brien Patrick · CIK 0001627183 · COO and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 363,375

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F8 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.42 to $40.80, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 7

O'Brien Patrick · CIK 0001627183 · COO and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 363,645

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F7 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.30 to $39.72, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 6

O'Brien Patrick · CIK 0001627183 · COO and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 363,945

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F6 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $39.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 5

O'Brien Patrick · CIK 0001627183 · COO and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,231

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F5 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.06 to $38.05, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 4

O'Brien Patrick · CIK 0001627183 · COO and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 372,125

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

SEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 3

O'Brien Patrick · CIK 0001627183 · COO and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 372,195

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.47 to $40.28, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 2

O'Brien Patrick · CIK 0001627183 · COO and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 372,695

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.03 to $38.89, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 1

O'Brien Patrick · CIK 0001627183 · COO and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,222

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.03 to $38.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002110 · doc4.xml · nonDerivative · entry 8

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,287

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.46 to $40.80, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002110 · doc4.xml · nonDerivative · entry 7

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,534

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.30 to $39.72, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002110 · doc4.xml · nonDerivative · entry 6

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,834

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.04 to $38.98, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002110 · doc4.xml · nonDerivative · entry 5

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,516

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.04 to $37.99, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002110 · doc4.xml · nonDerivative · entry 4

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,158

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.44 to $40.80, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002110 · doc4.xml · nonDerivative · entry 3

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,294

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.30 to $40.28, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002110 · doc4.xml · nonDerivative · entry 2

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,594

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.06 to $38.93, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002110 · doc4.xml · nonDerivative · entry 1

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,431

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.04 to $38.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-22-063020 · doc4.xml · nonDerivative · entry 1

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 336,704

F1 · shares: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-22-062530 · doc4.xml · derivative · entry 2

O'Brien Patrick · CIK 0001627183 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,000 shares

Expires 2026-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant.

SEC source: 0001209191-22-062530 · doc4.xml · nonDerivative · entry 1

O'Brien Patrick · CIK 0001627183 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 380,875

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-22-062241 · doc4.xml · nonDerivative · entry 2

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,720,714

F2 · shares: Includes 93,610 shares underlying restricted stock units, which will vest in four equal installments, with a commencement date of 12/20/22. Includes 140,415 underlying restricted stock units, that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part of in whole.

F3 · balance_after: Includes a total of 1,789,697 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.

SEC source: 0001209191-22-062241 · doc4.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,486,689

F1 · shares: Represents shares of stock which vested on the date of issuance.

SEC source: 0001209191-22-058469 · doc4.xml · nonDerivative · entry 2

San Martin Javier · CIK 0001794629 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,500

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.61 to $30.62, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-22-058469 · doc4.xml · nonDerivative · entry 1

San Martin Javier · CIK 0001794629 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,700

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.60 to $30.55, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-22-051551 · doc4.xml · nonDerivative · entry 2

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,468,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $31.25, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes a total of 1,649,282 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.

SEC source: 0001209191-22-051551 · doc4.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,469,856

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.21 to $31.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-22-041979 · doc4.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,508,938

F1 · shares: Modification of previously granted award from 800,000 to 248,803.

F2 · balance_after: Includes a total of 1,649,282 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.

SEC source: 0001209191-22-041850 · doc4.xml · derivative · entry 2

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 612,532

Underlying: Common Stock · 2,501 shares

Expires 2024-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant.

F3 · balance_after: Represents total stock options beneficially owned at various strike prices.

SEC source: 0001209191-22-041850 · doc4.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,060,135

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.

SEC source: 0001209191-22-051673 · doc5.xml · nonDerivative · entry 1

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 367,329

F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-22-009052 · doc4.xml · derivative · entry 6

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 615,033

Underlying: Common Stock · 146,388 shares

Expires 2022-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant.

F8 · balance_after: Represents total stock options beneficially owned at various strike prices.

SEC source: 0001209191-22-009052 · doc4.xml · nonDerivative · entry 5

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,057,634

F1 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.49 to $50.57, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F6 · balance_after: Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.

SEC source: 0001209191-22-009052 · doc4.xml · nonDerivative · entry 4

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,059,534

F1 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.58 to $51.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-22-009052 · doc4.xml · nonDerivative · entry 3

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,121,016

F1 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.60 to $51.61, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-22-009052 · doc4.xml · nonDerivative · entry 2

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,163,169

F1 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.63 to $53.61, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-22-009052 · doc4.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,204,022

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001209191-22-002617 · doc4.xml · derivative · entry 2

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 761,421

Underlying: Common Stock · 11,806 shares

Expires 2022-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant.

F3 · balance_after: Represents total stock options beneficially owned at various strike prices.

SEC source: 0001209191-22-002617 · doc4.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,057,634

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.

SEC source: 0001209191-22-002597 · doc4.xml · nonDerivative · entry 1

Waddill William D. · CIK 0001553338 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,150

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-22-002595 · doc4.xml · nonDerivative · entry 1

PERRY MICHAEL S · CIK 0001250379 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,900

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-22-002593 · doc4.xml · nonDerivative · entry 1

OLUKOTUN ADEOYE Y · CIK 0001242615 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,350

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-22-002590 · doc4.xml · nonDerivative · entry 1

GIVEN DOUGLAS B · CIK 0001156207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,268

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-22-002588 · doc4.xml · nonDerivative · entry 1

Ferrari Mauro · CIK 0001506045 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,971

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-22-002586 · doc4.xml · nonDerivative · entry 1

De Backer Marianne · CIK 0001797819 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,400

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-22-002290 · doc4.xml · nonDerivative · entry 4

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 464,005

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.82 to $64.35, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F6 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-22-002290 · doc4.xml · nonDerivative · entry 3

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 467,791

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.69 to $63.69, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-22-002290 · doc4.xml · nonDerivative · entry 2

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 471,569

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.63 to $62.63, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-22-002290 · doc4.xml · nonDerivative · entry 1

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 488,097

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.11 to $61.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-22-002284 · doc4.xml · nonDerivative · entry 10

Hamilton James C · CIK 0001830755 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,625

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F11 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-22-002284 · doc4.xml · nonDerivative · entry 9

Hamilton James C · CIK 0001830755 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,685

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.16 to $63.95, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-22-002284 · doc4.xml · nonDerivative · entry 8

Hamilton James C · CIK 0001830755 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,385

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.15 to $63.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.